---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-047748"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:45:49.250862+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis

## Summary
- Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.
- Rezafungin showed favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions.
- Target supplemental NDA submission to FDA in 2H26 based on ReSPECT results.
- CorMedix estimates US prophylaxis market opportunity for REZZAYO exceeds $2 billion.
- Mundipharma sponsored the trial; holds ex-US rights; Melinta (CorMedix sub) distributes in US.

## SEC filing metadata
- accession: 0001213900-26-047748
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/0001213900-26-047748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/ea0287640-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-047748
- JSON: https://secwatch.observer/filing/0001213900-26-047748.json
- Plain text: https://secwatch.observer/filing/0001213900-26-047748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.